AU2005235271A1 - Adjuvant composition and methods for its use - Google Patents

Adjuvant composition and methods for its use Download PDF

Info

Publication number
AU2005235271A1
AU2005235271A1 AU2005235271A AU2005235271A AU2005235271A1 AU 2005235271 A1 AU2005235271 A1 AU 2005235271A1 AU 2005235271 A AU2005235271 A AU 2005235271A AU 2005235271 A AU2005235271 A AU 2005235271A AU 2005235271 A1 AU2005235271 A1 AU 2005235271A1
Authority
AU
Australia
Prior art keywords
antigen
cat
cell activator
vaccine
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005235271A
Other languages
English (en)
Inventor
Jerome Tiollier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of AU2005235271A1 publication Critical patent/AU2005235271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2005235271A 2004-04-26 2005-04-25 Adjuvant composition and methods for its use Abandoned AU2005235271A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56495904P 2004-04-26 2004-04-26
US60/564,959 2004-04-26
US62906904P 2004-11-18 2004-11-18
US60/629,069 2004-11-18
PCT/IB2005/001485 WO2005102385A1 (en) 2004-04-26 2005-04-25 Adjuvant composition and methods for its use

Publications (1)

Publication Number Publication Date
AU2005235271A1 true AU2005235271A1 (en) 2005-11-03

Family

ID=34969994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005235271A Abandoned AU2005235271A1 (en) 2004-04-26 2005-04-25 Adjuvant composition and methods for its use

Country Status (8)

Country Link
US (1) US20070218086A1 (enExample)
EP (1) EP1761278B1 (enExample)
JP (1) JP2007534743A (enExample)
AT (1) ATE419008T1 (enExample)
AU (1) AU2005235271A1 (enExample)
CA (1) CA2564562A1 (enExample)
DE (1) DE602005012097D1 (enExample)
WO (1) WO2005102385A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
CN101146575A (zh) * 2005-03-22 2008-03-19 依奈特制药公司 新类型的γδT细胞活化剂及其应用
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
ITMI20060366A1 (it) * 2006-03-01 2007-09-02 C4T S C A R L Composti organo tiopirosfosfati metodo per prepararli e composizioni che li contengono
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
GB2453475B (en) * 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
EP2324040B1 (en) 2008-09-10 2014-01-01 Innate Pharma Novel polymorphic form of chdmapp, method of preparation thereof, and pharmaceutical composition comprising same
JP5676452B2 (ja) * 2008-09-29 2015-02-25 カディラ ファーマシューティカルズ リミテッド ワクチンアジュバント
GB0901411D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
AU2014233424B2 (en) * 2013-03-15 2017-03-16 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
KR102451441B1 (ko) * 2020-06-25 2022-10-12 대한민국 신규 면역증강제 및 이를 포함하는 백신 조성물
EP4173635A4 (en) * 2020-06-26 2024-04-17 Republic of Korea (Animal and Plant Quarantine Agency) Novel immunostimulant and vaccine composition comprising same
US20240261426A1 (en) * 2021-06-28 2024-08-08 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
GB202114311D0 (en) * 2021-10-06 2021-11-17 Molecular Attraction Ab New compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
BE1011282A3 (fr) * 1997-07-14 1999-07-06 Solvay Composition a base de polyethylene et procede de fabrication d'objets faconnes a partir de la composition.
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
CA2453817C (en) 2001-07-20 2011-09-20 Bioagency Ag Organophosphorus compounds for the activation of gamma/delta t-cells
WO2003009812A2 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20050042751A1 (en) * 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
FR2833266B1 (fr) 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
EP1426052B1 (en) 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
US7767842B2 (en) 2002-12-02 2010-08-03 Innate Pharma Sa Class of γδ T cells activators and use thereof
US20070025960A1 (en) * 2003-05-16 2007-02-01 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents

Also Published As

Publication number Publication date
CA2564562A1 (en) 2005-11-03
JP2007534743A (ja) 2007-11-29
US20070218086A1 (en) 2007-09-20
DE602005012097D1 (de) 2009-02-12
ATE419008T1 (de) 2009-01-15
EP1761278B1 (en) 2008-12-31
WO2005102385A1 (en) 2005-11-03
EP1761278A1 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
EP1761278B1 (en) Adjuvant composition and methods for its use
KR100764678B1 (ko) 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
US9061001B2 (en) Combination adjuvant formulation
KR102389489B1 (ko) Hiv 백신 제형
JP5230780B2 (ja) アジュバント混合製剤
CA2484049A1 (en) Imidazoquinoline adjuvants for vaccines
Ashhurst et al. Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against Mycobacterium tuberculosis
McInerney et al. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide
EP2303324A1 (en) Immunogenic composition
WO2020118159A1 (en) Methods and compositions comprising an nfkb inhibitor and an adjuvant
Wang et al. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes
JP4313847B2 (ja) 免疫賦活性イノシン一リン酸の５’−ヌクレオチダーゼ抵抗性誘導体およびその使用
WO2006067635A2 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
US9974852B2 (en) Mutated non-primate lentiviral Env proteins and their use as drugs
EP1767214B1 (en) Use of neurotrophil activating protein of helicobacter pylori (HP-NAP) and/or of its portions as adjuvants for the development of T helper type 1 (TH1) immune responses
US20190194278A1 (en) Novel immunostimulating peptides
US20060165687A1 (en) Vaccine adjuvant
EP2987502A1 (en) Peptide adjuvants
US20080085261A1 (en) Vaccine Adjuvant
Moureau et al. Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly (DL-lactide-co-glycolide) microparticles
US20050037015A1 (en) Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus
EP2331104A2 (en) Method of inducing an anti-viral immune response

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application